Crosslinked zwitterionic hydrogels

US9394435B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9394435-B2
Application numberUS-201414457801-A
CountryUS
Kind codeB2
Filing dateAug 12, 2014
Priority dateNov 6, 2009
Publication dateJul 19, 2016
Grant dateJul 19, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Zwitterionic crosslinking agents, crosslinked zwitterionic hydrogels prepared from copolymerization of zwitterionic monomers with the zwitterionic crosslinking agent, methods for making crosslinked zwitterionic hydrogels, and devices that include and methods that use the crosslinked zwitterionic hydrogels.

First claim

Opening claim text (preview).

The embodiments of the invention in which an exclusive property of privilege is claimed are defined as follows: 1. A crosslinked hydrogel, comprising a crosslinked polymer having repeating units and a plurality of crosslinks, wherein each crosslink is represented by the formula: wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, fluorine, trifluoromethyl, C1-C6 alkyl, and C6-C12 aryl groups; R 3 is selected from the group consisting of C1-C6 alkyl, C6-C12 aryl, CH 2 ═C(R 1 )-L 1 -, CH 2 ═C(R 2 )-L 2 -, or R 3 is the residual portion of a third crosslink, -L 1 -CR 1 —CH 2 — or -L 2 -CR 2 —CH 2 —; L 1 and L 2 are independently selected from the group consisting of —C(═O)O—(CH 2 ) n — and —C(═O)NH—(CH 2 ) n —, wherein n is an integer from 1 to 20; L 3 is —(CH 2 ) n —, where n is an integer from 1 to 20; A 1 is C, S, SO, P, or PO; x is an integer from about 5 to about 10,000; X − is the counter ion associated with the N + cationic center; and M + is a counterion associated with the (A=O)O − anionic center. 2. The hydrogel of claim 1 , wherein R 1 , R 2 , and R 3 are independently selected from the group consisting of C1-C3 alkyl. 3. The hydrogel of claim 1 , wherein L 1 and L 2 are —C(═O)O—(CH 2 ) n —, wherein n is 1-6. 4. The hydrogel of claim 1 , wherein L 3 is —(CH 2 ) n —, where n is an integer from 1-6. 5. The hydrogel of claim 1 , wherein A 1 is C or SO. 6. The hydrogel of claim 1 , wherein M + at each occurrence is a metal or organic ion. 7. The hydrogel of claim 1 , wherein X − at each occurrence is selected from the group consisting of halide, carboxylate, alkylsulfonate, sulfate, nitrate, perchlorate, tetrafluoroborate, hexafluorophosphate, trifluoromethylsulfonate, bis(trifluoromethylsulfonyl)amide, lactate, and salicylate. 8. The hydrogel of claim 1 , wherein x is an integer from about 10 to about 1,000. 9. The hydrogel of claim 1 , wherein the hydrogel is a gradient hydrogel. 10. A surface of a substrate, wherein the surface comprises a hydrogel of claim 1 . 11. The surface of claim 10 , wherein the substrate is selected from the group consisting of a medical device, a glucose sensor, a particle, a drug carrier, non-viral gene delivery system, a biosensor, a membrane, an implantable sensor, a subcutaneous sensor, an implant, and a contact lens. 12. The surface of claim 11 , wherein the particle is a nanoparticle. 13. The hydrogel of claim 1 , further comprising a particle encapsulated therein. 14. The hydrogel of claim 13 , wherein the particle is a nanoparticle. 15. The hydrogel of claim 14 , wherein the nanoparticle has a diameter of about 5 nm to about 200 nm. 16. The hydrogel of claim 14 , wherein the nanoparticle is a gold nanoparticle. 17. The hydrogel of claim 14 , wherein the nanoparticle is a polymer-coated nanoparticle. 18. The hydrogel of claim 17 , wherein the nanoparticle is coated with a polymer comprising carboxybetaine methacrylate (CBMA) or oligo(ethylene glycol) methyl ether methacrylate (OEGMA). 19. The hydrogel of claim 1 , wherein each repeating unit has the formula: wherein R 4 is selected from the group consisting of hydrogen, fluorine, trifluoromethyl, C1-C6 alkyl, and C6-C12 aryl groups; R 5 and R 6 are independently selected from the group consisting of hydrogen, alkyl, and aryl, or taken together with the nitrogen to which they are attached form a cationic center; L 4 is a linker that covalently couples the cationic center [N + (R 5 )(R 6 )] to the polymer backbone [—(CH 2 —CR 4 ) n —]; L 5 is a linker that covalently couples the anionic center [A 2 (═O)—O − ] to the cationic center; A 2 is C, S, SO, P, or PO; M + is a counterion associated with the (A 2 =O)O − anionic center; X − is a counter ion associated with the cationic center; n is an integer from 5 to about 10,000. 20. The hydrogel of claim 19 , wherein R4, R5, and R6 are independently selected from the group consisting of C1-C3 alkyl. 21. The hydrogel of claim 19 , wherein L4 is selected from the group consisting of —C(═O)O—(CH2)n- and —C(═O)NH—(CH2)n-, wherein n is an integer from 1 to 20. 22. The hydrogel of claim 19 , wherein L5 is —(CH2)n-, where n is an integer from 1 to 20. 23. The hydrogel of claim 19 , wherein n is an integer from 10 to about 1,000. 24. The hydrogel of claim 19 , wherein M+ at each occurrence is a metal or organic ion. 25. The hydrogel of claim 19 , wherein X— at each occurrence is selected from the group consisting of halide, carboxylate, alkylsulfonate, sulfate, nitrate, perchlorate, tetrafluoroborate, hexafluorophosphate, trifluoromethylsulfonate, bis(trifluoromethylsulfonyl)amide, lactate, and salicylate.

Assignees

Inventors

Classifications

  • by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays · CPC title

  • by a single or double bond to nitrogen · CPC title

  • Glucose oxidase (1.1.3.4) · CPC title

  • acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1) · CPC title

  • Of polyester [e.g., alkyd, etc.] · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9394435B2 cover?
Zwitterionic crosslinking agents, crosslinked zwitterionic hydrogels prepared from copolymerization of zwitterionic monomers with the zwitterionic crosslinking agent, methods for making crosslinked zwitterionic hydrogels, and devices that include and methods that use the crosslinked zwitterionic hydrogels.
Who is the assignee on this patent?
Univ Washington Ct Commerciali
What technology area does this patent fall under?
Primary CPC classification A61L27/34. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jul 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).